Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms.
作者信息
Jevremovic Dragan, Shi Min, Horna Pedro, Otteson Gregory E, Timm Michael M, Baughn Linda B, Greipp Patricia T, Gonsalves Wilson I, Kapoor Prashant, Gertz Morie A, Binder Moritz, Buadi Francis K, Zhou Jiehao, Dispenzieri Angela, Kourelis Taxiarchis, Muchtar Eli, Rajkumar S Vincent, Kumar Shaji K, Olteanu Horatiu
机构信息
Division of Hematopathology, Mayo Clinic, Rochester, MN, USA.
Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
出版信息
Blood Cancer J. 2024 Jul 31;14(1):126. doi: 10.1038/s41408-024-01113-8.
Abstract
摘要
相似文献
1
Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms.流式细胞术评估浆细胞肿瘤微小残留病的实际敏感性
Blood Cancer J. 2024 Jul 31;14(1):126. doi: 10.1038/s41408-024-01113-8.
2
Accuracy of Bone Marrow Flow Cytometry Analysis in Patients With Plasma Cell Neoplasm in Thailand: A Single Institutional Study.泰国浆细胞肿瘤患者骨髓流式细胞术分析的准确性：一项单机构研究
Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):e27-37. doi: 10.1016/j.clml.2015.12.002. Epub 2015 Dec 17.
3
Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease.流式细胞术用于微小残留病常规评估时灵敏度的提高。
Haematologica. 2010 Apr;95(4):691-2. doi: 10.3324/haematol.2009.018911. Epub 2009 Nov 30.
4
An analysis of the false negative rate of minimal residual disease measurement by multiparameter flow cytometry in multiple myeloma.多参数流式细胞术检测多发性骨髓瘤微小残留病的假阴性率分析
Int J Lab Hematol. 2020 Apr;42(2):e65-e67. doi: 10.1111/ijlh.13112. Epub 2019 Sep 20.
5
Utility of nine-color, 11-parameter flow cytometry for detection of plasma cell neoplasms: a comparison with bone marrow morphologic findings and concurrent M-protein studies in serum and urine.九色、十一参数流式细胞术在浆细胞肿瘤检测中的应用：与骨髓形态学检查以及同期血清和尿液中 M 蛋白研究的比较。
Am J Clin Pathol. 2014 Sep;142(3):398-410. doi: 10.1309/AJCPO5GQPXF8QCEC.
6
Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.多参数流式细胞术对浆细胞异常增殖性疾病的诊断及微小残留病的监测
Clin Lab Med. 2017 Dec;37(4):821-853. doi: 10.1016/j.cll.2017.08.001.
7
Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry.通过免疫球蛋白测序检测到的微小残留病比流式细胞术更有效地预测慢性淋巴细胞白血病复发。
Leuk Lymphoma. 2018 Aug;59(8):1986-1989. doi: 10.1080/10428194.2017.1397664. Epub 2017 Nov 22.
8
A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma.一种用于检测骨髓瘤微小残留病的单管六色流式细胞术筛查检测方法。
Leukemia. 2007 Sep;21(9):2046-9. doi: 10.1038/sj.leu.2404815. Epub 2007 Jul 26.
9
Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.在常规血液学实践中使用8色流式细胞术方案检测慢性淋巴细胞白血病患者的微小残留病。
Int J Lab Hematol. 2014 Apr;36(2):165-71. doi: 10.1111/ijlh.12149. Epub 2013 Sep 13.
10
Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.套细胞淋巴瘤中微小残留病的检测：与共识性IGH聚合酶链反应相比，四色流式细胞术在初始分期及随访检查中的方法及意义
Haematologica. 2008 Apr;93(4):551-9. doi: 10.3324/haematol.11267.
引用本文的文献
1
Peripheral Blood Flow Cytometry-based Definition of Plasma Cell Leukemia.基于外周血流式细胞术的浆细胞白血病定义
Leukemia. 2025 May 26. doi: 10.1038/s41375-025-02653-z.
2
Attitudes and perspectives of oncologists about measurable residual disease testing in multiple myeloma: initiative for standardizing guidelines.肿瘤学家对多发性骨髓瘤中可测量残留病检测的态度和观点：规范指南倡议
Bone Marrow Transplant. 2025 May 5. doi: 10.1038/s41409-025-02604-3.
3
A review on pathobiology of circulating tumour plasma cells: The sine qua non of poor prognosis in plasma cell neoplasms.循环肿瘤浆细胞的病理生物学综述：浆细胞肿瘤预后不良的必要条件。
Oncol Res. 2025 Apr 18;33(5):1055-1068. doi: 10.32604/or.2024.055154. eCollection 2025.
本文引用的文献
1
Utility of flow cytometry screening before MRD testing in multiple myeloma.多发性骨髓瘤中微小残留病检测前流式细胞术筛查的效用。
Blood Cancer J. 2023 Apr 20;13(1):55. doi: 10.1038/s41408-023-00832-8.
2
Eight-color multiparameter flow cytometry (EuroFlow-NGF) is as sensitive as next-generation sequencing in detecting minimal/measurable residual disease in autografts of patients with multiple myeloma.八色多参数流式细胞术（EuroFlow-NGF）在检测多发性骨髓瘤患者自体移植物中的微小/可测量残留病方面与下一代测序一样敏感。
EJHaem. 2023 Jan 24;4(1):184-191. doi: 10.1002/jha2.633. eCollection 2023 Feb.
3
Cancer statistics, 2022.癌症统计数据，2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
4
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.一项大型荟萃分析确立了 MRD 阴性在多发性骨髓瘤患者长期生存结局中的作用。
Blood Adv. 2020 Dec 8;4(23):5988-5999. doi: 10.1182/bloodadvances.2020002827.
5
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.比较下一代测序（NGS）和下一代流式（NGF）在多发性骨髓瘤微小残留病（MRD）评估中的应用。
Blood Cancer J. 2020 Oct 30;10(10):108. doi: 10.1038/s41408-020-00377-0.
6
Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.对 clonoSEQ 检测方法在急性淋巴细胞白血病、慢性淋巴细胞白血病和多发性骨髓瘤中建立可测量（最小）残留病的分析评估。
BMC Cancer. 2020 Jun 30;20(1):612. doi: 10.1186/s12885-020-07077-9.
7
ClonoSEQ Cleared for Residual Cancer Testing.ClonoSEQ检测获批准用于残留癌症检测。
Cancer Discov. 2018 Dec;8(12):OF6. doi: 10.1158/2159-8290.CD-NB2018-136. Epub 2018 Oct 16.
8
Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation.浆细胞增生指数可预测干细胞移植治疗免疫球蛋白轻链淀粉样变性的结局。
Haematologica. 2018 Jul;103(7):1229-1234. doi: 10.3324/haematol.2018.189985. Epub 2018 Apr 19.
9
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.用于高灵敏度和标准化检测多发性骨髓瘤微小残留病的新一代流式检测技术。
Leukemia. 2017 Oct;31(10):2094-2103. doi: 10.1038/leu.2017.29. Epub 2017 Jan 20.
10
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
Zotero 插件